Hemostasis associated with abnormalities of fibrinolysis

Blood Reviews

Volumn 3, Issue 1, 1989, Pages 11-17

  Aoki, N ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; PLASMIN; PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID;

FIBRINOLYSIS; HEMOSTASIS; HUMAN; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANTIFIBRINOLYTIC AGENTS; FIBRINOLYSIS; HEMORRHAGIC DISORDERS; HEMOSTASIS; HUMAN; THROMBOSIS;

EID: 0024538918     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0268-960X(89)90021-0     Document Type: Article

References (43)

1. Inhibitors of fibrinolytic enzyme system
2. Fibrinolysis: Its initiation and regulation
3. Genetic abnormalities of fibrinolytic system
4. 2-plasmin inhibitor associated with severe hemorrhagic tendency
5. 2-plasmin inhibitor
6. 2-plasmin inhibitor in three sisters
7. Hereditary abnormalities of the fibrinolytic system
8. 2-antiplasmin
9. 2-antiplasmin: Functional characterization and metabolism in a heterozygote deficient patient
10. 2-antiplasmin deficiency
11. 2-antiplasmin
12. 2-antiplasmin deficiency
13. 2-antiplasmin
14. 2-antiplasmin deficiency
15. 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder
16. 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis
17. Influence of factor XIIIa activity on human whole blood clot lysis in vitro
18. Plasma activator of plasminogen: Cause of a familial bleeding diathesis
19. A new life-long hemorrhagic disorder due to excess plasminogen activator
20. Inherited fibrinolytic disorder due to an enhanced plasminogen activator level
21. Increased fibrinolysis and amyloidosis
22. Pathologic hyperfibrinolysis associated with amyloidosis: Clinical response to epsilon amino caproic acid
23. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis
24. 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma
25. Clinical significance of accelerated fibrinolysis in liver disease
26. 2-plasmin inhibitor levels in liver diseases
27. Plasminogen activators in alcoholic cirrhosis: Demonstration of increased tissue type and urokinase type activator
28. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: A critical role for tissue plasminogen activator inhibitor
29. 2-plasmin inhibitor in fibrinolytic states
30. 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase
31. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency
32. A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall
33. A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis
34. Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor
35. A family with thrombosis associated with high level of tissue plasminogen activator inhibitor (Abstract)
36. Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis
37. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis
38. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis
39. Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis
40. Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia
41. A new type of congenital dysfibrinogenemia with defective fibrin lysis-Dusard syndrome: possible relation to thrombosis
42. Dysfibrinogenemia (fibrin Dusard) associated with impaired fibrin-enhanced plasminogen activation
43. 2-plasmin inhibitor deficiency